Epigenomic pathways in cancer and in cancer immunotherapy

Add to your list(s) Download to your calendar using vCal

• Shelley Berger, Epigenetics Institute, Departments of Cell and Developmental Biology, Genetics, Biology, University of Pennsylvania
• Thursday 23 February 2017, 16:00-17:00
• CRUK CI Lecture Theatre.

If you have a question about this talk, please contact Kate Davenport.

PLEASE NOTE CHANGE OF TIME: 16:00

Cancer is both a genomic and epigenomic disease, given that numerous chromatin pathways have been implicated as drivers in cancer. Our study of p53 in human cancer has revealed an important role of epigenomic regulation in several cancers involving gain-of-function mutant p53, and in teratocarcinoma cancer, which involves wild type p53. In the former case, mutant p53 drives expression of gene-activating histone modifiers, and in the latter case, wild type p53 is modified by gene-repressive modifications – in both cases permitting the expression of growth accelerating genes and pathways. Immunotherapy is a new and exciting area of clinical cancer treatment. While some individuals respond, others show resistance. We are investigating epigenetic pathways that may inhibit effective cancer immunotherapy, and other epigenetic pathways that may provide exceptionally potent response.

This talk is part of the Cancer Research UK Cambridge Institute (CRUK CI) Seminars in Cancer series.

This talk is included in these lists:

• All Talks (aka the CURE list)
• Biology
• CCC talks for website
• CRUK CI Lecture Theatre
• CRUK CI Seminars
• Cancer Research UK Cambridge Institute (CRUK CI) Seminars in Cancer
• Graduate-Seminars
• Liam
• Life Sciences
• Life Sciences
• ME Seminar
• PMRFPS's
• cri
• my_list
• other talks
• se393's list
• sfm36

Note that ex-directory lists are not shown.